Both NK- and T-cell subsets are already known to have integral roles in the mediation and mechanisms of action of currently explored immunotherapies, particularly those of IMiDs and mAbs—including elotuzumab, daratumumab and anti-CD137 mAbs.38, 39, 40 The argument for such immunotherapeutic approaches has been supported by recent findings from massively parallel sequencing of tumor samples from MM patients. Here, TNFRSF9 is linked to Miyoshi myopathy.